Literature DB >> 1533

Prognostic factors in polyarteritis.

M Sack, J T Cassidy, G G Bole.   

Abstract

The clinical course of 40 patients with polyarteritis was reviewed to determine prognostic factors and response to treatment. The first three months were the most critical to survival. Survivorship was 57 per cent at five years. Older age of onset, involvement of skeletal muscle and presence of peripheral neuropathy weighted against a satisfactory outcome. Cutaneous vasculitis was associated with a more benign course. Myocardial disease, central nervous system involvement, or hypertension were not invariably poor prognostic factors. Muscle biopsies, even in the absence of clinical involvement, were a useful diagnostic procedure, and renal angiograms were found to be a valuable alternative to renal biopsy. An unequivocal distinction on clinical and histopathologic criteria could not be made among polyarteritis nodosa, hypersentitivity angiitis, and allergic granulomatosis. Australia antigenemia occurred in six per cent of patients. Although evaluation of therapy was difficult, data from this study did not show a superiority of high vs. low dosage of corticosteroids in suppressing active disease.

Entities:  

Mesh:

Year:  1975        PMID: 1533

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Central nervous system polyarteritis nodosa.

Authors:  M R Rosenberg; M Parshley; S Gibson; R Wernick
Journal:  West J Med       Date:  1990-11

2.  Vasculitic leg ulcers associated with diltiazem.

Authors:  A J Carmichael; C J Paul
Journal:  BMJ       Date:  1988 Aug 20-27

3.  Clinical features, treatment and outcome of polyarteritis nodosa.

Authors:  A Reeves; B Bresnihan
Journal:  Ir J Med Sci       Date:  1987-03       Impact factor: 1.568

4.  Localized polyarteritis nodosa: cases involving the lower extremities and the breast.

Authors:  A Levy; A Weinberger; C Mor; J Pinkhas
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

5.  Cyclophosphamide treatment in polyarteritis nodosa.

Authors:  P Oriente; A Riccio; C Farinaro; E Farinaro; R Scarpa; L Vignone; A Pucino
Journal:  Clin Rheumatol       Date:  1986-06       Impact factor: 2.980

6.  Polyarteritis nodosa associated with streptococcus.

Authors:  J David; B M Ansell; P Woo
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.